Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs

Globally, it is estimated that 71.1 million people have chronic hepatitis C virus (HCV) infection, including an estimated 7. 5 million people who have recently injected drugs (PWID). There is an additional large, but unquantified, burden among those PWID who have ceased injecting. The incidence of H...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Int J Drug Policy
Main Authors: Grebely, Jason, Bruneau, Julie, Lazarus, Jeffrey V., Dalgard, Olav, Bruggmann, Philip, Treloar, Carla, Hickman, Matthew, Hellard, Margaret, Roberts, Teri, Crooks, Levinia, Midgard, Håvard, Larney, Sarah, Degenhardt, Louisa, Alho, Hannu, Byrne, Jude, Dillon, John F., Feld, Jordan J., Foster, Graham, Goldberg, David, Lloyd, Andrew R., Reimer, Jens, Robaeys, Geert, Torrens, Marta, Wright, Nat, Maremmani, Icro, Norton, Brianna L., Litwin, Alain H., Dore, Gregory J.
פורמט: Artigo
שפה:Inglês
יצא לאור: 2017
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6049820/
https://ncbi.nlm.nih.gov/pubmed/28683982
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.drugpo.2017.05.019
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים